Bringing hope through science

Jakob interviewed by Di.TV - as new CEO about going forward

In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.

See the interview (Swedish) or read the transcript

Jakob Lindberg appointed CEO

On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.

Read the press release

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Webcast - Oncopeptides withdraw Pepaxto in US, scale down organization and focus on R&D

October 22, Oncopeptides announced that the company has decided to withdraw Pepaxto^® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.

Investors, financial analysts, and media were invited to participate in a webcast including a Q&A the same day.

The event was hosted by CEO Marty J Duvall, CMO Klaas Bakker and CSO Jakob Lindberg. The presentation was held in English and was recorded.

More info, presentation and the webcast link

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more